Drug
Camostat
Camostat is a pharmaceutical drug with 6 clinical trials. Historical success rate of 33.3%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 2 completed trials
Completion Rate
33%(2/6)
Active Trials
0(0%)
Results Posted
250%(5 trials)
Terminated
4(67%)
Phase Distribution
Ph phase_2
5
83%
Ph phase_3
1
17%
Phase Distribution
0
Early Stage
5
Mid Stage
1
Late Stage
Phase Distribution6 total trials
Phase 2Efficacy & side effects
5(83.3%)
Phase 3Large-scale testing
1(16.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
33.3%
2 of 6 finished
Non-Completion Rate
66.7%
4 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(2)
Terminated(4)
Detailed Status
Terminated4
Completed2
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
33.3%
Most Advanced
Phase 3
Trials by Phase
Phase 25 (83.3%)
Phase 31 (16.7%)
Trials by Status
terminated467%
completed233%
Recent Activity
0 active trials
Showing 5 of 6
terminatedphase_2
The Potential of Camostat in COVID-19
NCT04625114
completedphase_2
ACTIV-2: A Study for Outpatients With COVID-19
NCT04518410
terminatedphase_2
A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
NCT04455815
terminatedphase_2
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol
NCT04662073
completedphase_2
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
NCT04662086
Clinical Trials (6)
Showing 6 of 6 trials
NCT04625114Phase 2
The Potential of Camostat in COVID-19
NCT04518410Phase 2
ACTIV-2: A Study for Outpatients With COVID-19
NCT04455815Phase 2
A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
NCT04662073Phase 2
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol
NCT04662086Phase 2
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
NCT04730206Phase 3
The DAWN Antivirals Trial for Ambulatory COVID-19 Patients
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6